Purpose: To evaluate the clinical efficacy of ultrasound-guided percutaneous microwave ablation therapy (PMWA) for symptomatic uterine fibroids in a multicenter study. were prospectively studied to compare the reduction rate of uterine fibroids, hemoglobin level and uterine fibroid symptom and health-related quality of life questionnaire (UFS-QOL) scores before and at 3, 6, and 12 months after ablation.
Introduction
Uterine leiomyoma is the most common gynecologic benign tumor. Uterine fibroids are the most common myomas in women of childbearing age, with a reported incidence of 20-77% [1, 2] . Most myomas are asymptomatic, but they can cause certain significant symptoms such as menorrhagia, secondary anemia and pelvic pressure. At present, the primary treatment methods are administration of gonadotropin-releasing hormone analogs, myomectomy, hysterectomy and uterine artery embolization. In addition, as an ever-expanding alternative, thermal ablation therapy includes microwave ablation, high-intensity focused ultrasonography, and radiofrequency ablation [1, 3] . Patients who wish to preserve the uterus opt for minimally invasive therapies such as uterine artery embolization and in situ ultrasound (US)-guided thermal ablation.
US-guided percutaneous microwave ablation (PMWA) therapy utilizes electromagnetic microwave heat to induce cellular death via coagulation necrosis.
Single-center research studies have confirmed the safety and efficacy of this treatment; it has been shown that this treatment is effective, minimally invasive and uterus-conserving with effective relief of clinical symptoms after therapy [4] [5] [6] [7] [8] [9] [10] [11] .
However, no multicenter study with a large sample has been conducted to confirm the conclusions of these single-center investigations. To fill this gap, we have conducted a prospective study across multiple treatment centers in China to evaluate the clinical efficacy of PMWA for the treatment of uterine fibroids.
Materials and Methods
This study has been approved by the Ethics Committee of the Chinese PLA General Hospital (ratification No. 2012036, registration No. ChiCTR-ONC-12002968).
Enrollment criteria for the treatment centers
One of the criteria was that the staff at the hospital should be trained in standard operating procedures and data collection at the Interventional Ultrasound Department of the Chinese PLA General Hospital (the standard procedures are set by multiple centers together). The second criterion was that the annual number of uterine fibroid
cases treated at each center should be at least 20.
Patient enrollment criteria
Patients diagnosed with uterine fibroids through MRI and US at each treatment center were recruited between January 2013 and August 2015. The inclusion criteria were (1) leiomyoma-related symptoms such as menorrhagia, secondary anemia, and urinary frequency; (2) a strong desire to preserve the uterus; (3) no response to medication or other conservative treatment; (4) no use of hormonal drugs within the first 3 months of ablation; (5) absence of peri-menopausal signs; and (6) availability of a safe abdominal puncture path. The exclusion criteria were (1) menstruation, pregnancy, or lactation; (2) plans for future pregnancy; (3) fibroids that grew rapidly in the short term; (4) cervical intraepithelial neoplasia (CIN) III; (5) malignant neoplasm of any organ; (6) uncontrolled acute pelvic inflammation; (7) dysfunction of vital organs (e.g., heart, brain, liver or kidney); and (8) severe coagulation disorder.
Instruments
The instruments used were a KV2000 MW tumor coagulator (Nanjing Kangyou Medical Instruments Co., China) and an ECO-100C Microwave System (Nanjing ECO Microwave System Co. Ltd., China).
Sonography system
The Acuson Sequoia 512 (Siemens AG, Germany), Acuson S2000 (Siemens AG, Germany), LOGIQ E9 (General Electric Company, America), MyLab_Twice (Esaote S.p.A., Italy), and HI_VISION_Preirus (Hitachi, Ltd., Japan) were used.
Contrast agent
SonoVue (Bracco, Italy) was used. 
Methods used to induce anesthesia
Anesthesia was induced via intravenous conscious sedation (induction: midazolam 1.0 mg, sulfentanyl 10 µg, propofol 1.0 mg/kg; maintenance: propofol 4-10 mg/kg·h) and local infiltration (2% lidocaine 3.0-5.0 ml).
Treatment procedures
Patients adopted a supine position for the treatment. Under US guidance, one or two microwave antennas were inserted into the fibroid, depending on its size. The output energy of the microwave was set to induce ablation. The entire ablation process was monitored via real-time ultrasonography. The ablation procedure was discontinued when the hyper-echo (caused by microbubbles during microwave emission and roughly representing the ablation field [12] ) covered the entire nodule. CEUS was performed immediately to preliminarily evaluate the ablation effect. If the contrast enhancement was found to be within the lesion, supplemental ablation was immediately performed.
Effectiveness assessment
1. Assessment of the ablation effect: The myoma length, width and height were measured via CEUS before ablation and immediately after ablation; then, the volume of the fibroid and the ablation zone were calculated. The formulae were as follows:
Mean diameter = (length + width + height)/3; Volume = 4/3 × π × r 3 , where r is the mean radius (mean diameter/2);
Ablation rate = volume of the non-enhanced field in the lesion immediately after ablation/volume of the lesion before ablation × 100%.
Assessment of the clinical effect:
(1) Assessment times: 3, 6, and 12 months after ablation 2) Hemoglobin levels before and after treatment.
3) The uterine fibroid symptom and health-related quality of life questionnaire (UFS-QOL) as reported by Spies et al. in 2002 [13] . This instrument includes a symptom severity score (SSS) and a health-related quality of life (HRQL) score. The patients completed the questionnaire by themselves before and after treatment.
Statistical analysis
Each treatment center uploaded monthly data of the eligible via e-mail. All statistical analyses were performed using SPSS version 17.0. The quantitative data were described as means ± SD and were tested using the t-test if the data followed a normal distribution; if not, the Wilcoxon signed rank sum test was used. P < 0.05 was considered to indicate statistical significance.
Results

General characteristics
Eight Chinese treatment centers treating a total of 344 patients were included. Six patients were excluded due to the lack of a safe window. Twenty-three of the enrolled patients were lost to follow-up. Therefore, 311 patients were ultimately included in the statistical analysis. The age of the patients ranged from 29 to 55 years (mean, 41 ± 5.11 years). Two hundred thirty-two patients had one fibroid, 48 patients had two fibroids, and 31 patients had three or more fibroids. A total of 405 leiomyomas were treated. Thirty-seven leiomyomas were not treated because their mean diameter was less than 2 cm. The mean diameter ranged from 2.03 to 12.50 cm (mean ± SD, 5.10 ± were treated twice to ensure that the ablation was successful. The other patients received only one round of treatment, during which the lesion was completely ablated. The CEUS examination conducted after ablation showed no enhancement in the ablation area, but a circular enhancement was observed at the periphery of the fibroid (Figure 1 ). The time to discharge ranged from 4 to 7 days (mean ± SD, 5.43 ± 0.89 days). For 46 patients, discharge of necrotic masses from the vagina occurred 7-270 days after ablation. Among these patients, 21 had type 1/2 fibroids and 25 had type 3/4 fibroids. The mean volume of the mass was 6.91 ± 8.73 cm 3 and the volume of the largest mass was 32.97 cm 3 . The masses were discharged entirely in ten patients with type 1/2 fibroids and four patients with type 3/4 fibroids, while masses were discharged partially in the other patients.
Effectiveness of the ablation
The mean ablation rate of the myomas was 86.6% (54.0-100%).
Clinical efficacy
The fibroid volumes, hemoglobin levels, and UFS-QOL scores are shown in Table 1 .
The differences in these parameters between baseline and posttreatment were statistically significant (P < 0.05). The mean myoma reduction rate was 63.5%, 78.5%
and 86.7% at 3, 6, and 12 months after treatment, respectively.
Complications and side effects
No major complications occurred during ablation and follow-up. Twenty-seven patients (8.68%) experienced grade 1 (Common Terminology Criteria for Adverse Events (CTCAE) v4.0 of the National Cancer Institute) lower abdominal pain, which can be tolerated and which disappeared within 12 hours. Nineteen patients (6.11%) had a small amount of vaginal secretion. These secretions resolved within 20 days after ablation.
Discussion
PMWA is a minimally invasive treatment that involves in situ inactivation of tumors.
In response to the applied electrical field of microwaves, the rotation of dipole molecules and ionic polarization produce friction and heat, thus inducing cellular death via coagulation necrosis [15] . This technology has been widely used to treat solid tumors of the liver, spleen, thyroid, and other organs [16] [17] [18] [19] [20] [21] [22] [23] [24] . In 2011,
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Zhang et al. [5] studied PMWA therapy for uterine fibroids and confirmed its safety and efficacy.
To avoid the subjective bias of a single-center study, this study summarizes data from multiple treatment centers and objectively evaluates the clinical efficacy of PMWA. The effectiveness of ablation was evaluated via CEUS. At present, contrast-enhanced MRI is considered the gold standard for evaluating the effect of thermal ablation. A pathological study showed that the coagulated necrotic area corresponded to the zone of non-contrast enhancement [15, 25] . CEUS can objectively reflect perfusion of the microcirculation in tissue. Studies have shown high consistency between CEUS and contrast-enhanced MRI with regard to evaluation of the ablation effect, and CEUS could therefore be used as an alternative to contrast-enhanced MRI for evaluation of the ablation zone [26, 27] . Moreover, CEUS is a convenient, real-time, dynamic procedure, so residual lesions can be found immediately after the treatment, after which further ablation treatment can be performed.
Uterine leiomyoma is a benign lesion, so the main purpose of treatment is to relieve clinical symptoms and improve patient quality of life. In this study, the mean ablation rate was 86.6%. In some fibroids, the ablation rate was less than 60%. This is because only partial ablation was performed in some cases depending on the location and size of the fibroid; in particular, complete ablation was not performed in the case of fibroids that were in a relatively unsafe position such as close to the bowel or bladder. Partial ablation was primarily undertaken to ease clinical symptoms and avoid serious complications.
The volume of the myomas decreased significantly after treatment. The reduction rate at 6 months after ablation was 78.5%, which is consistent with that of a previous single-center study [5] . The reduction rate at 12 months was 86.7%, which is slightly lower than the rate of 93.1% reported previously but higher than that of 74.5%
reported over the same period for intramural leiomyomas [11] . This is because the percentage of patients with complete sarcoid discharges in the present study was 4.50%, which is lower than the percentage of 10.0% reported in a previous study [5] . During ablation and 12 months of follow-up, no major complications occurred.
The discharge of necrotic tissue was considered to be a cure for the disease [7] .
Vaginal secretion could be caused by liquefaction of the necrotic tissue and by irritation and inflammation of the endometrium.
In summary, PMWA is a convenient, effective, and minimally invasive therapy for FIGO type 1-6 uterine fibroids. PMWA has the added advantage of rapid recovery, and it significantly improves patient quality of life. These characteristics make PMWA therapy worthy of popularization and application as a minimally invasive treatment method for uterine fibroids. 
